Home › Research › Risk genes beyond APOE
Mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la Enfermedad de Alzheimer. Revisión Sistemática
María José Tapia, Carem Prieto. MQRInvestigar, 2025-08-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introducción: La enfermedad de Alzheimer se considera una de las patologías neurodegenerativas de mayor impacto en la salud pública, con una prevalencia y tasa de mortalidad en incremento. En su forma de inicio temprano, se ha vinculado estrechamente con mutaciones genéticas que alteran el procesamiento de la APP y por ende acumulación de placas Aβ, siendo los genes PSEN1 y PSEN2 los más implicados. Objetivo: Analizar la evidencia disponible sobre mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la enfermedad de Alzheimer. Metodología: Se realizó una revisión sistemática de la literatura, incluyendo estudios publicados entre 2019 y 2024, identificados a través de las bases de datos Scopus, PubMed y Taylor & Francis. La selección de estudios siguió los lineamientos PRISMA, y la calidad metodológica fue evaluada mediante la escala Newcastle-Ottawa (NOS). Resultados: Los estudios incluidos reportaron mutaciones frecuentes en PSEN1 (E280A, M146I, T274K) y en menor medida en PSEN2 (M239T), asociadas con una mayor proporción Aβ42/Aβ40 y un incremento en la acumulación de placas amiloides en tejido cerebral. Conclusiones: Las mutaciones en PSEN1 y PSEN2 se pueden considerar potenciales marcadores moleculares útiles para el diagnóstico temprano y la estratificación del riesgo en pacientes con sospecha de Alzheimer de origen genético.
What this study adds
Evidence grade: Low
This systematic review reports that mutations in PSEN1 and PSEN2 are linked to a higher Aβ42/Aβ40 ratio and more amyloid plaque buildup in brain tissue. The authors conclude these mutations may serve as molecular markers for early diagnosis and risk stratification in people with suspected genetic Alzheimer's, though the review itself does not test any treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tapia, M. J., & Prieto, C. (2025). Mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la Enfermedad de Alzheimer. Revisión Sistemática. MQRInvestigar. https://doi.org/10.56048/mqr20225.9.3.2025.e946
Vancouver
Tapia MJ, Prieto C. Mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la Enfermedad de Alzheimer. Revisión Sistemática. MQRInvestigar. 2025. doi:10.56048/mqr20225.9.3.2025.e946.
BibTeX
@article{tapia2025-741ba39d,
author = {Tapia, María José and Prieto, Carem},
title = {{Mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la Enfermedad de Alzheimer. Revisión Sistemática}},
journal = {MQRInvestigar},
year = {2025},
doi = {10.56048/mqr20225.9.3.2025.e946},
url = {https://doi.org/10.56048/mqr20225.9.3.2025.e946}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Objetivo: Analizar la evidencia disponible sobre mutaciones en los genes PSEN1 y PSEN2 como marcadores moleculares en la enfermedad de Alzheimer.
- Metodología: Se realizó una revisión sistemática de la literatura, incluyendo estudios publicados entre 2019 y 2024, identificados a través de las bases de datos Scopus, PubMed y Taylor & Francis.
- La selección de estudios siguió los lineamientos PRISMA, y la calidad metodológica fue evaluada mediante la escala Newcastle-Ottawa (NOS).
- Resultados: Los estudios incluidos reportaron mutaciones frecuentes en PSEN1 (E280A, M146I, T274K) y en menor medida en PSEN2 (M239T), asociadas con una mayor proporción Aβ42/Aβ40 y un incremento en la acumulación de placas amiloides en tejido cerebral.
- Conclusiones: Las mutaciones en PSEN1 y PSEN2 se pueden considerar potenciales marcadores moleculares útiles para el diagnóstico temprano y la estratificación del riesgo en pacientes con sospecha de Alzheimer de origen genético.
Why it matters
This systematic review reports that mutations in PSEN1 and PSEN2 are linked to a higher Aβ42/Aβ40 ratio and more amyloid plaque buildup in brain tissue. The authors conclude these mutations may serve as molecular markers for early diagnosis and risk stratification in people with suspected genetic Alzheimer's, though the review itself does not test any treatment.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (MQRInvestigar) |
| Journal's citation record | 0 / 4 | MQRInvestigar: journal h-index 10 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Carem Prieto: h-index 7 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidad Católica de Cuenca: institution h-index 55 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Risk genes beyond APOE from nearby years
Also in Risk genes beyond APOE
104 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.